Helicos BioSciences (HLCS) Announces Publication of Breakthrough Study Using Helicos(TM) Genetic Analysis System to Sequence Human Genome
More News related to HLCS
- Helicos BioSciences (HLCS) Sells Genetic Analysis System to Dutch Research Collaborative
- Helicos BioSciences Announces the Sale of a Helicos(R) Genetic Analysis System to the Leiden University Medical Center in the Netherlands
- Unusual 11 Mid-Day Movers 11/11: NCST, SMI, MSN, CHLN Higher; TONE, RHIE, CLWR, STV Lower
- Helicos BioSciences (HLCS) Files $50M Shelf Registration
- Helicos BioSciences (HLCS) Announces Filing of 10-Q; Disengages in Sale of Company
More News related to Corporate News
- Hydrogenics Resumes Trading Under NASDAQ Symbol "HYGS"
- Varian Medical (VAR) to Highlight its New Range of Detectors at Annual RSNA Meeting in Chicago
- Manulife (MFC) Confirms No Exposure to Dubai World
- Activision's (ATVI) Call of Duty Amasses $3 Billion in Global Sales
- Seiko Epson to Transfer Sales Function of Small and Medium-Sized TFT LCD Business to Sony (SNE)
Helicos BioSciences Corporation (NASDAQ: HLCS) announced late yesterday the publication of a breakthrough study in which a Helicos(TM) Genetic Analysis System was used to sequence a human genome at the Stanford Institute for Stem Cell and Regenerative Medicine. The research article, now appearing in the on-line edition of Nature Biotechnology, demonstrates the power, accuracy and ease-of-use of the Helicos System.
The study, conducted by Dmitry Pushkarev, Norma Neff and Stephen Quake was carried out using less than four runs of a single HeliScope(TM) Single Molecule Sequencer, and achieved 28X average coverage of the human genome. The sequencing allowed the detection of over 2.8 million single nucleotide polymorphisms, of which over 370,000 were novel. Validation with a genotyping array demonstrated 99.8% concordance. The unbiased nature of the single-molecule sequencing approach also allowed the detection of 752 copy number variations in this genome.
"Helicos is very proud of this achievement and congratulates the Stanford group on their study; personal genome resequencing is another in a continuing series of major breakthroughs for our team as we bring the only true single-molecule sequencing available today to the market" said Ron Lowy, CEO of Helicos.
Related Categories
Corporate NewsMomentum Movers
Stocks Mentioned
+0.04Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
